Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Cystic Fibrosis · Hepatitis C

Vertex Pharmaceuticals (Australia)

Vertex Pharmaceuticals (Australia) Pty.

Vertex Pharmaceuticals (Australia) clinical programs — 61 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
Status
Public
HQ
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
Founded
1989
Employees
6,304
Programs
159
Drugs
64
Patents
991
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Vertex Pharmaceuticals (Australia) projects

61 ClinicalTrials.gov programs sponsored by Vertex Pharmaceuticals (Australia).

Vertex Pharmaceuticals (Australia) has 61 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

61 programs

Clinical programs

Page 1 of 2

  1. ALPN-101

    Vertex Pharmaceuticals (Australia) Pty.

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  2. AVN944

    Vertex Pharmaceuticals (Australia) Pty.

    Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  3. CTX001-121

    Vertex Pharmaceuticals (Australia) Pty.

    Severe sickle cell disease (SCD)

    phase 2 small molecule active

    1 trial

  4. Cethrin

    Vertex Pharmaceuticals (Australia) Pty.

    Spinal Cord Injury

    phase 2 small molecule completed

    1 trial

  5. Inaxaplin

    Vertex Pharmaceuticals (Australia) Pty.

    Proteinuric Kidney Disease

    phase 2 small molecule active

    1 trial

  6. Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial

  7. Ivacaftor 150 MG

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  8. Ivacaftor 25 mg/75 mg

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  9. MP-424 (Telaprevir)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  10. Merimepodib

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  11. P-1037

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  12. Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  13. Placebo (matched to VX-121 suspension)

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  14. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  15. Ribavirin

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  16. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  17. Telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  18. Telaprevir and Sofosbuvir

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  19. Tezacaftor/Ivacaftor + Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  20. VC-02 Combination Product

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus With Hypoglycemia

    phase 2 other completed

    1 trial

  21. VCH-222 or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  22. VCH-759 (BCH-27759)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  23. VX-121

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  24. VX-135

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    3 trials

  25. VX-147

    Vertex Pharmaceuticals (Australia) Pty.

    Glomerulosclerosis, Focal Segmental

    phase 2 small molecule completed

    1 trial

  26. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 2 small molecule completed

    2 trials

  27. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  28. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Small Fiber Neuropathy

    phase 2 small molecule completed

    1 trial

  29. VX-152

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  30. VX-222

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C Virus

    phase 2 small molecule completed

    2 trials

  31. VX-264

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  32. VX-264 Implant

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  33. VX-371

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Ciliary Dyskinesia

    phase 2 small molecule completed

    1 trial

  34. VX-371 + HS

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  35. VX-407

    Vertex Pharmaceuticals (Australia) Pty.

    Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    phase 2 small molecule active

    4 trials

  36. VX-407 tablet

    Vertex Pharmaceuticals (Australia) Pty.

    Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    phase 2 small molecule active

    1 trial

  37. VX-522 mRNA therapy

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial

  38. VX-548

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 2 small molecule completed

    2 trials

  39. VX-548

    Vertex Pharmaceuticals (Australia) Pty.

    Painful Lumbosacral Radiculopathy

    phase 2 small molecule completed

    1 trial

  40. VX-561

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule terminated

    2 trials

  41. VX-659

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  42. VX-661

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  43. VX-670

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy Type 1 (DM1)

    phase 2 small molecule active

    2 trials

  44. VX-670 Solution for Injection/Infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  45. VX-702

    Vertex Pharmaceuticals (Australia) Pty.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    2 trials

  46. VX-765

    Vertex Pharmaceuticals (Australia) Pty.

    Psoriasis

    phase 2 small molecule completed

    1 trial

  47. VX-765

    Vertex Pharmaceuticals (Australia) Pty.

    Partial Epilepsy

    phase 2 small molecule completed

    1 trial

  48. VX-765 Part A

    Vertex Pharmaceuticals (Australia) Pty.

    Epilepsy

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Vertex Pharmaceuticals (Australia) have?

61 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.